Who is sponsoring NCT05430477?

NCT05430477 is sponsored by Ryan J. Halter.

What drugs are being tested in NCT05430477?

Interventions in NCT05430477: Electrical impedance imaging using Non-Significant Risk device (EII probe).

What condition does NCT05430477 study?

NCT05430477 studies Oral Lesion.

Is NCT05430477 still recruiting?

NCT05430477 is currently completed. Last updated 22 September 2025.

Last reviewed 2025-09-22 · How we verify

NCT05430477

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Characterizing In Vivo Oral Lesion Impedances

Completed Last updated 22 September 2025

What this trial tests

trial testing Electrical impedance imaging using Non-Significant Risk device (EII probe) in Oral Lesion in 114 participants. Completed in 20 August 2025.

Timeline

29 August 2022

Primary endpoint
30 June 2025

20 August 2025

Quick facts

Lead sponsor	Ryan J. Halter
Status	Completed
Study type	OBSERVATIONAL
Enrollment	114
Start date	29 August 2022
Primary completion	30 June 2025
Estimated completion	20 August 2025
Sites	1 location across United States

Drugs / interventions tested

Electrical impedance imaging using Non-Significant Risk device (EII probe)

Conditions studied

Oral Lesion — all drugs for Oral Lesion →

Sponsor

Ryan J. Halter

Who can join

18 and older, any sex, with Oral Lesion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to demonstrate a significant difference in electrical impedance between normal, benign, premalignant, and malignant oral lesions using a custom device. The secondary study objective is to create a database of in vivo electrical impedance spectra and images of oral lesions. This will be achieved by collecting Electrical Impedance sensing data and images from two cohorts of patients: Cohort I will consist of 200 patients undergoing oral lesion biopsies and Cohort II will be comprised of 50 patients scheduled for oral cancer resection. A maximum of 5 additional subjects will be initially enrolled in each Cohort to optimize data acquisition.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

In Vivo Classification of Oral Lesions Using Electrical Impedance Spectroscopy.
Lloyd SA, Lee TE, Murphy EK, Doussan AF, et al · · 2026 · PMID 40536863 · DOI 10.1109/tbme.2025.3581465

Verify or expand the search:

Other Ryan J. Halter trials

Trials by the same sponsor.

NCT06381505 — RetracTOR/ Retractor for Image Guided Trans-Oral Surgery · recruiting
NCT06039085 — Microendoscopic EI Sensing for Real-time Intraoperative Surgical Margin Assessment · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05430477 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ryan J. Halter
Last refreshed: 22 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05430477.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing